Sun Pharmaceutical and Zydus Lifesciences shares could see pressure on Monday as both companies have issued limited recall for some pharmaceutical products in the US market.

Prabhudas Lilladher has reaffirmed a BUY rating for Sun Pharmaceutical Industries with a revised target price of Rs 2,275.

Sun Pharmaceutical Industries jumped during the afternoon session with the stock price gaining over 3 percent.

On Monday, domestic stock markets experienced a severe drop as the S&P BSE Sensex fell over 1,100 points in morning trade, eventually sliding 1,300 points to 78,420, while the NSE Nifty50 decli

Prabhudas Lilladher reaffirms its "Buy" stance on Sun Pharmaceutical Industries Ltd. (SUNP), revising the target price to Rs.2,100 from Rs.1,885.

ITC, Axis Bank, Asian Paints, TCS and Sun Pharmaceuticals were offering support to markets in today’s trading session.